Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                International Programs News, Speeches, and Publications

International Programs News, Speeches, and Publications

                        


                        From a Global Perspective Home
          International Programs
          International Programs News, Speeches, and Publications
          Bookmark this Site! FDA’s Comprehensive Database on Antiretroviral Drugs for HIV under PEPFARInternational Programs News, Speeches, and Publications Bookmark this Site! FDA’s Comprehensive Database on Antiretroviral Drugs for HIV under PEPFAR
  
  	
    Share
    Post
    Linkedin

    Email
    PrintFROM A GLOBAL PERSPECTIVE

*By Gabrielle Lamourelle and Capt. Mary E. Kremzner*

December 1, 2020

From a Global Perspective

This World AIDS Day is an opportunity to highlight the availability of an important FDA resource on those antiretroviral (ARV) drugs approved or tentatively approved by FDA and eligible for procurement under the President’s Emergency Plan for AIDS Relief or PEPFAR.

On January 29, 2020, the agency established an interactive PEPFAR Database to provide, for the first time, FDA-reviewed product labeling and packaging information for each approved or tentatively-approved ARV drug product. Prior to the launch of the PEPFAR Database, only basic information about these products was available in a static web table. We recognized the need for improved access to the existing product information, as well as for providers, patients and procurers in nations around the world to easily access added content such as updates on manufacturing sites, shelf-life, storage conditions, current manufacturing status for the finished ARV drug, and much more.

The FDA’s mobile-friendly database has modernized and increased access to information about life-saving antiretrovirals for HIV under the PEPFAR program.
FDA modeled this database after the popular Drugs@FDA Database which provides information about FDA-approved drugs for use in the United States. The product labeling includes, for example, information about dosage and administration, warnings and precautions, contraindications, adverse events, pediatric use, and more, all provided with the authorization of each company that sponsored the application. This searchable database offers interactive dashboards, provides real-time insight into key metrics in case a user wants to conduct data analysis, and also allows users to download the labeling information.

PEPFAR was created in 2003 to bring together the federal government agencies involved in fighting the HIV/AIDS epidemic by creating comprehensive, coordinated and targeted interventions in hard-hit countries. Since PEPFAR’s launch, low-cost, quality-assured, life-saving ARV drugs have been provided through the program to nearly 15.7 million people worldwide, including almost 700,000 children.

FDA plays an integral role in PEPFAR by ensuring safe and effective ARV drugs are available for procurement through PEPFAR so these drugs can get to populations in countries with the highest burden of disease in a timely manner. Since 2004, FDA has encouraged sponsors worldwide to submit U.S. marketing applications for single entity, fixed-combination, and co-packaged versions of previously approved ARV drugs. To minimize delays in approval, FDA uses its existing processes including expedited review for PEPFAR ARV drugs, while ensuring that these products meet the same standards as similar products for the U.S. market and our own population. This review often results in FDA issuing tentative approval for drugs intended for PEPFAR; that denotes the drug cannot be sold inside the United States due to intellectual property protections but can be made available to the international community.

Responsibility for the PEPFAR program is distributed across FDA. The Office of Global Policy and Strategy serves as the FDA point of contact with all outside entities in coordinating agency activities dealing with PEPFAR, including those associated with drug firms seeking to participate in the expedited review process for ARV drugs. The Center for Drug Evaluation and Research, or CDER, approves and tentatively approves ARV drugs that are then available for procurement under PEPFAR and CDER’s Division of Drug Information (DDI) maintains the interactive database. Since the database was launched in January, DDI has implemented 31 updates, revisions or modifications.

Recognizing that not all users may have ready access to a computer, a mobile-friendly version of the database is available as well. In announcing the database in January, FDA Commissioner Stephen Hahn said providing this tool was “consistent with our efforts to modernize and improve access to information and unleash the power of data.”

Since the launch, the database has been utilized by stakeholders 7,381 times and FDA hopes that the information in the database continues to be invaluable to public health stakeholders in the international HIV communities. Although an analysis of the users to date finds that the database has been only lightly accessed by those located in countries that rely on PEPFAR support, we believe that the usefulness of the information in the database is yet to be fully explored by local providers and patients.

PEPFAR Database: a pie chart showing the number of visitors to the database by country. Percentages are United States: 32 percent; India: 30 percent; China: 7 percent; Switzerland: 3 percent; The Netherlands: 3 percent; and all others: 18 countries with less than 2 percent of visits each.
Before this launch we had heard anecdotally that due to the tentatively approved status of most ARV drugs available for procurement under PEPFAR, prescribers were forced to make patient treatment decisions without the full labeling available, including information on dosage and administration. We view the database as offering an easily accessible way for providers to get the information they need right at their fingertips.

We recognize that the database was launched only weeks before the beginning of the COVID-19 pandemic, which has naturally dominated the attention of procurers, providers and patients. Going forward, we will be looking for ways to get the word out about this useful information resource and ask our stakeholders to consider ways to do the same. We’ll also be adding new features to the PEPFAR Database based on stakeholder feedback and hope you will check back often to see what’s new.

After all, the PEPFAR program’s continued success in combating HIV will rely on data and information-driven approaches – just what the PEPFAR Database represents.

Additional information:

World AIDS Day 2020: FDA Continues to Drive Advances in Care and Work with the Global Public Health Community

*Gabrielle Lamourelle, MPH, is the acting director of the Office of Global Diplomacy and Partnerships in FDA’s Office of Global Policy and Strategy*

*Capt. Mary E. Kremzner, PharmD, MPH, BCGP, is director of the Division of Drug Information, Office of Communications, in FDA’s Center for Drug Evaluation and Research*

                                                                                  Content current as of:
      12/01/2020International Programs News, Speeches, and Publications

          
                        


                        From a Global Perspective
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop